Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis

Frontiers in Pain Research

Pain Research

Nicola Maffulli¹  Ashim Gupta²  Anish G. Potty³ 

[1] Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, Fisciano, Italy;San Giovanni di Dio e Ruggi D’Aragona Hospital “Clinica Orthopedica” Department, Hospital of Salerno, Salerno, Italy;Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Queen Mary University of London, London, United Kingdom;School of Pharmacy and Bioengineering, Keele University School of Medicine, Stoke-on-Trent, United Kingdom;Regenerative Orthopaedics, Noida, India;Future Biologics, Lawrenceville, GA, United States;BioIntegrate, Lawrenceville, GA, United States;South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX, United States;South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX, United States;

关键词: platelet-rich plasma;    PRP;    allogenic PRP;    umbilical cord blood;    osteoarthritis;    knee osteoarthritis;    hip osteoarthritis;    regenerative medicine;   

DOI  :  10.3389/fpain.2023.1216190

 received in 2023-05-03, accepted in 2023-06-01,  发布年份 2023

来源: Frontiers

【 摘 要 】

Osteoarthritis (OA) induces tremendous amounts of stress and financial burden on patients and healthcare systems worldwide. Current treatments have limitations and do not address the etiopathogenetic cause of OA. Regenerative medicine may circumvent limitations posed by traditional modalities and relies on the utilization of biologics including platelet-rich plasma (PRP). Several peer-reviewed studies have documented the safety and efficacy of autologous PRP in mitigating symptoms in knee and hip OA patients. Nonetheless, only few studies investigated the safety and efficacy of allogenic PRP. This mini review summarizes the outcomes of preclinical and clinical studies using allogenic PRP for treatment of knee or hip OA. We identified 3 preclinical and 1 clinical study using allogenic PRP for treatment of knee OA, and only 1 clinical study using allogenic PRP for treatment of hip OA. Administration of allogenic PRP is safe and probably efficacious in patients with knee or hip OA. However, more pre-clinical studies and high-powered, multi-center, non-randomized and randomized controlled trials with extended follow-up are warranted to further establish the safety and efficacy of allogenic PRP to justify its clinical use.

【 授权许可】

Unknown   
© 2023 Gupta, Potty and Maffulli.